30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q13 Revenue: Wright Medical

$60.6MM, +17% (U.S. $42.6MM, +5%; ex-U.S. $17.9MM, +60%)

  • Foot/Ankle $37.3MM, +30% (U.S. +15%, ex-U.S. +94%)
  • Upper Extremity $6.0MM, -2% (U.S. +1%, ex-U.S. -11%)
  • Biologics $15.0MM, -2% (U.S. -16%, ex-U.S. +53%)
  • Other $2.0MM, +62% (U.S. +69%, ex-U.S. +58%)
  • Discontinued operations (hips/knees) -12% (Hips -14%, Knees -10%)

 

  • 1st quarter of U.S. upper extremities growth since 2Q11
  • Foot/ankle supported by new products, U.S. performance of INBONE total ankle and PRO-TOE hammertoe system, which both grew ~25%, and initial stocking order from new distribution partner in China
  • Launched ORTHOLOC 3Di ankle fusion system
  • Divestiture of hip/knee business to Microport Scientific enables focus on extremities/biologics
  • No additional information on Augment Bone Graft PMA submission
  • Salesforce productivity at ~$0.76MM/direct rep, up from ~$0.6MM in 2011